Chronic Kidney Disease Treatment Market Research, 2032
The global chronic kidney disease treatment market size was valued at $32 billion in 2022, and is projected to reach $47.9 billion by 2032, growing at a CAGR of 4% from 2023 to 2032.
Chronic kidney disease (CKD) is a long-term condition characterized by the gradual loss of kidney function over time. The kidneys play a crucial role in filtering waste products, excess fluids, and toxins from the bloodstream, while also helping regulate blood pressure, electrolyte balance, and the production of red blood cells.
CKD typically develops slowly and progresses through different stages, ranging from mild to severe, based on the level of kidney function. The most common causes of CKD include diabetes, high blood pressure (hypertension), and certain kidney infections or conditions. Thus, chronic kidney disease (CKD) treatment refers to a range of medical interventions and strategies aimed at managing and slowing the progression of kidney damage and its associated complications.
The major factor driving the chronic kidney disease treatment market size is the higher prevalence of CKD cases. For instance, in 2021, according to the Centers for Disease Control and Prevention (CDC), it was stated that more than 1 in 7 (15%) of the U.S. adults or 37 million people had chronic kidney disease. Furthermore, global prevalence of CKD has been steadily rising due to factors such as rise in aging population, the increase in prevalence of diabetes and hypertension (major risk factors for CKD), and changes in lifestyle and dietary patterns. Thus, the prevailing cases are anticipated to drive the market growth.
Moreover, surge in geriatric population is another key factor driving the growth of the chronic kidney disease treatment industry. The geriatric population who are at major risk for the development and progression of CKD and rise in adoption of advanced treatments are expected to further drive the market growth. For instance, according to the Centers for Disease Control and Prevention (CDC), chronic kidney disease affects most common people aged 65 or older (38%), followed by people aged 45 to 64 years (12%) and people aged 18 to 44 years (6%).
In addition, the changing lifestyle habits, such as smoking, excessive alcohol consumption, poor diet choices, and inadequate physical activity, can contribute to the development and progression of CKD. These habits can lead to conditions such as hypertension, diabetes, and obesity, which are major risk factors for CKD. Thus, increased demand for chronic kidney disease treatment industry is driving the market growth.
Furthermore, growing awareness and early detection of chronic kidney disease (CKD) play a crucial role in managing the disease and driving improvements in patient outcomes. In recent years, efforts to increase public awareness about CKD and its risk factors have been on the rise. Education campaigns, screening programs, and community outreach initiatives have contributed to a greater understanding of the importance of early detection and intervention.
By raising awareness, individuals at risk of CKD, such as those with diabetes, hypertension, or a family history of kidney disease, are encouraged to undergo regular screenings and seek medical attention if they experience symptoms or risk factors. Early detection allows healthcare providers to intervene promptly, implement appropriate treatments, and develop personalized management plans. Thus, such initiatives are propelling the market growth.
However, the high cost of treatment for chronic kidney disease (CKD) poses a significant hindrance to market growth. The expenses associated with medications, dialysis, and kidney transplantation can be substantial, limiting access to optimal care for many individuals. Additionally, limited access to healthcare and inadequate healthcare infrastructure in certain regions further exacerbate the challenges. These factors hinder timely diagnosis and management of CKD, as individuals may face difficulties in accessing healthcare facilities and specialized services; thus, restraining the growth of the market.
The outbreak of COVID-19 had a negative effect on the market expansion for chronic kidney disease treatment market. Lockdowns, social distancing measures, and overwhelmed healthcare systems have caused disruptions in regular healthcare services, including routine check-ups, consultations, and follow-up visits. These disruptions may have affected the management and monitoring of CKD patients. In addition, Patients with CKD are considered a high-risk group for severe COVID-19 infection due to their compromised immune system and underlying health conditions. The increased vulnerability of CKD patients to COVID-19 may have resulted in a heightened need for precautions, hospitalizations, and adjustments to their treatment plans.
However, adoption of in-home dialysis and telemedicine promoted social distancing measures by reducing the need for CKD patients to travel to dialysis centers or healthcare facilities for regular treatments and check-ups has potentially driven the chronic kidney disease treatment market growth. This helps mitigate the risk of virus spread and aligns with public health guidelines to maintain physical distancing. In addition, telemedicine enables healthcare providers to remotely monitor and assess CKD patients' conditions. Through virtual consultations and remote monitoring, healthcare professionals can ensure continuous care, provide guidance, and make necessary adjustments to treatment plans without requiring patients to visit the hospital or clinic in person.
The chronic kidney disease treatment market forecast is segmented on the basis of treatment, end user, and region. On the basis of treatment, the market is classified into drug class and dialysis. The drug class is further categories into ACE Inhibitors, Erythropoietic Stimulating agents, Diuretics, and Other (phosphate binder, beta blockers, calcium channel blockers). As per end user, the market is segmented into Hospitals, Dialysis Centers and others (homecare and research and academic institutes). Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By treatment, the drugs segment accounted for largest chronic kidney disease treatment market share and is projected to register the highest CAGR during the forecast period. The advancements, including the introduction of new drugs and therapies, contribute significantly to the growth of the CKD treatment market. Further, the availability of a diverse range of drug classes helps healthcare professionals tailor treatment plans to individual patient needs, driving improved outcomes and market expansion.
By End User
Depending on end user, the hospitals & clinics segment accounted for largest chronic kidney disease treatment market share in 2022 and is expected to remain dominant throughout the forecast period. This is attributed to the growth as it is a primary healthcare provider and is often equipped with specialized departments and facilities dedicated to the diagnosis, treatment, and management of CKD.
Region wise, North America dominated the chronic kidney disease treatment market in 2022 and is expected to continue the trend throughout the forecast period. This is attributed to the rise in prevalence of CKD, presence of key players, and availability of high-quality healthcare system & modern medical technologies. However, Asia-Pacific is expected to register the highest CAGR during the forecast period, owing to the presence of a large patient population, growth in awareness about potential of chronic kidney disease treatment, and increase in healthcare funding.
Presence of several major players such as AstraZeneca plc, Pfizer Inc., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, and Fresenius SE and Co. KGaA and advancement in manufacturing technology for development of effective treatment devices in the region are expected to drive the growth of the market. Furthermore, the presence of well-established healthcare infrastructure and rise in adoption rate of dialysis technology are expected to drive the market growth. Furthermore, various product approvals and contract agreements as key strategies adopted by the key players in this region boost the growth of the market.
Asia-Pacific offers profitable chronic kidney disease treatment market opportunity for key players owing to rise in technological advancements. Further , the market growth in this region is attributed to a rise in incidence of chronic kidney disease and a rise in adoption of the regular checkups carried out by most prevailing population. Thus, there is an increase in demand for primary care services such as diagnosis and treatment centers that focus on preventing chronic kidney diseases.
Moreover, the region has become a hub for kidney disease owing to a large growth in the geriatric population base and diverse patient pool. Furthermore, the rise in R&D activities as well as the well-established presence of domestic companies in the region are expected to provide notable opportunities for the market growth. In addition, a rise in contract manufacturing organizations within the region is expected to provide lucrative opportunities for new entrants in this region.
Competitive analysis and profiles of the major players in the chronic kidney disease treatment market such as AstraZeneca plc, Pfizer Inc. Johnson & Johnson, F. Hoffmann-La Roche Ltd., Baxter International Inc., Becton, Dickinson and Company, B. Braun SE, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Fresenius SE and Co. KGaA. Key players operating in the market have adopted product approval, acquisition, and product launch as their key strategies to expand their product portfolio.
Recent Product Approval in Chronic kidney disease treatment market
In May 2023, AstraZeneca’s Farxiga (dapagliflozin) received approval in the U.S. to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA) was based on positive results from the DELIVER Phase III trial.
In February 2023, AstraZeneca’s Forxiga (dapagliflozin) received approval in the European Union to extend the indication for heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of left ventricular ejection fraction (LVEF), including HF with mildly reduced and preserved ejection fraction (HFmrEF, HFpEF).
In September 2022, AstraZeneca's Forxiga received approval in China to reduce the risk of sustained estimated glomerular filtration rate ((eGFR)) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression with and without type-2 diabetes (T2D).
In April 2022, Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, received the U.S. Food and Drug Administration (FDA) clearance for the VersiPD Cycler System1. This next-generation portable automated peritoneal dialysis system is the lightest, smallest, and quietest dialysis cycler in the U.S.
Recent Acquisition in Chronic kidney disease treatment market
In March 2022, B. Braun SE, one of the world’s leading medical technology companies acquired Intermedt Medizin &; Technik GmbH, a specialist in the preparation of dialysis concentrates. With this acquisition the Intermedt product portfolio will be permanently integrated into B. Braun comprehensive range of products and services for dialysis therapy.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chronic kidney disease treatment market analysis from 2022 to 2032 to identify the prevailing chronic kidney disease treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the chronic kidney disease treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global chronic kidney disease treatment market trends, key players, market segments, application areas, and market growth strategies.
Chronic kidney disease treatment Market Report Highlights
Market Size By 2032
USD 47.9 billion
CAGR of 4%
2022 - 2032
By End User
Key Market Players
AbbVie Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Becton, Dickinson and Company, Fresenius SE and Co. KGaA, B. Braun SE, Baxter International Inc., AstraZeneca plc, Pfizer Inc., Teva Pharmaceutical Industries Ltd.
This section provides various opinions in chronic kidney disease treatment market. In accordance with several interviews conducted, the utilization of such medicines is projected to witness a significant rise with growth in the number of chronic kidney disease patients across the globe. It is expected to witness high demand for the drugs, owing to rise in cases of chronic kidney disorders such as kidney stones, kidney failure, and kidney cancer. The kidney disorder treatments are getting better and more advanced than their predecessors, owing to rising activities in the R&D segments of the key players.
The chronic kidney disease treatment market has gained momentum in the research, innovation, and development sectors, owing to surge in the number of chronic kidney disorders across the globe, significant technological advancements, and surge in the product launches, business expansions & FDA approvals among nephrology product manufacturing companies and other organizations. In addition, rise in awareness regarding treatments for chronic kidney diseases and their advantages supplement the market growth.
According to the perspectives of leading companies in the market, the demand for chronic kidney diseases has increased significantly due to rising cases of patients. Moreover, the introduction of novel drugs and improvements in the existing products are propelling the market growth. However, inclination of generic drugs is proving a big challenge for the global market.
North America dominated the chronic kidney disease treatment market in 2022 and is expected to continue the trend throughout the forecast period. This is attributed to the rise in prevalence of CKD, presence of key players, and availability of high-quality healthcare system & modern medical technologies. However, Asia-Pacific is expected to register the highest CAGR during the forecast period, owing to the presence of a large patient population, growing awareness about potential of chronic kidney disease treatment, and increase in healthcare funding.